All Stories

  1. Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway
  2. SERS Quantification and Characterization of Proteins and Other Biomolecules
  3. Importance of the surface chemistry of nanoparticles on peroxidase-like activity
  4. Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation
  5. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions
  6. Rapid and Robust Quantification of p-Xyleneselenocyanate in Plasma via Derivatization
  7. Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice
  8. Switch of Steady-State to an Accelerated Granulopoiesis in Response to Androctonus australis hector Venom
  9. Dose optimization of G-CSF
  10. Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging
  11. Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice
  12. Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee
  13. Development and biodistribution of a theranostic aluminum phthalocyanine nanophotosensitizer
  14. Commentary: Impact of a deletion of the full-length and short isoform of p75NTR on cholinergic innervation and the population of postmitotic doublecortin positive cells in the dentate gyrus
  15. Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation
  16. Personalized Treatment: The Future of Medicine. A Perspective on the Preconditioning for Stem Cell Transplantation
  17. Transplanted Bone Marrow-Derived Cells Contribute to Human Adipogenesis
  18. Fluorescence labeled microbubbles for multimodal imaging
  19. DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line
  20. Complement activation is involved in the hepatic injury caused by high-dose exposure of mice to perfluorooctanoic acid
  21. The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model
  22. Immunotoxicological effects of streptozotocin and alloxan: In vitro and in vivo studies
  24. Rat islets are not rejected by anti-islet antibodies in mice treated with costimulation blockade
  25. Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging
  26. Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation
  27. Personalized medicine in cancer therapy
  28. Real-Time Assessment of Tissue Hypoxia In Vivo with Combined Photoacoustics and High-Frequency Ultrasound
  29. From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development
  30. The nanoparticulateQuillajasaponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells
  31. Comparison of Algorithms for Oral Busulphan Area Under the Concentration–Time Curve Limited Sampling Estimate
  32. Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice
  33. Biodistribution, kinetics, and biological fate of SPION microbubbles in the rat
  34. Activation of Wnt/β-Catenin Pathway in Monocytes Derived from Chronic Kidney Disease Patients
  35. Sub-acute, moderate-dose, but not short-term, low-dose dietary pre-exposure of mice to perfluorooctanoate aggravates concanavalin A-induced hepatitis
  36. The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease
  37. Thermostable Luciferase from Luciola cruciate for Imaging of Carbon Nanotubes and Carbon Nanotubes Carrying Doxorubicin Using in Vivo Imaging System
  38. Multimodality imaging using SPECT/CT and MRI and ligand functionalized 99mTc-labeled magnetic microbubbles
  39. Both sub-acute, moderate-dose and short-term, low-dose dietary exposure of mice to perfluorooctane sulfonate exacerbates concanavalin A-induced hepatitis
  40. Skin Cancer Detection Using Temperature Variation Analysis
  41. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation
  42. Gas chromatographic–mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine
  43. Busulphan-Cyclophosphamide Cause Endothelial Injury, Remodeling of Resistance Arteries and Enhanced Expression of Endothelial Nitric Oxide Synthase
  44. Inhibition of proteasome deubiquitinating activity as a new cancer therapy
  45. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
  46. N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro
  47. Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning
  50. Liver Circadian Clock, a Pharmacologic Target of Cyclin-Dependent Kinase Inhibitor Seliciclib
  51. The influence of interferon-α on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma
  52. Dynamics of Fat Cell Turnover in Humans
  53. Evaluation of Immune Responses to Seasonal Influenza Vaccination in Healthy Volunteers and in Patients After Stem Cell Transplantation
  54. Dynamics of fat cell turnover in humans
  55. Rapid and Sensitive Method for Determination of Cyclophosphamide in Patients Plasma Samples Utilizing Microextraction by Packed Sorbent Online with Liquid Chromatography‐Tandem Mass Spectrometry (MEPS‐LC‐MS/MS)
  56. Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cells
  57. Cyclophosphamide Pharmacokinetics in Mice: A Comparison Between Retro Orbital Sampling Versus Serial Tail Vein Bleeding
  58. Simultaneous Determination of Busulphan in Plasma Samples by Liquid Chromatography‐electrospray Ionization Mass Spectrometry Utilizing Microextraction in Packed Syringe (MEPS) as On‐line Sample Preparation Method
  59. Higher Plasma but not Intracellular Concentrations After Infusion With Liposomal Daunorubicin Compared With Conventional Daunorubicin in Adult Acute Myeloid Leukemia
  60. Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients
  61. A pharmacodynamic study of 5-azacytidine in the P39 cell line
  62. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
  63. Myeloablative and immunosuppressive properties of treosulfan in mice
  64. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma
  65. Stability, pKa and plasma protein binding of roscovitine
  66. Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta
  67. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat
  68. Microextraction in packed syringe/liquid chromatography/electrospray tandem mass spectrometry for quantification of olomoucine in human plasma samples
  69. Development and validation of a liquid chromatography and tandem mass spectrometry method for determination of roscovitine in plasma and urine samples utilizing on-line sample preparation
  70. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice
  71. Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice
  72. Lung Epithelial Cells and Type II Pneumocytes of Donor Origin After Allogeneic Hematopoietic Stem Cell Transplantation
  73. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
  74. Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat
  75. On-Line Derivatization Utilizing Solid-Phase Microextraction (SPME) for Determination of Busulphan in Plasma Using Gas Chromatography–Mass Spectrometry (GC-MS)
  76. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes
  77. Effect of cyclophosphamide on gene expression of cytochromes P450 and β-actin in the HL-60 cell line
  78. Simple Method Based on Fluorescent Detection for the Determination of 4-Hydroxycyclophosphamide in Plasma
  79. The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo
  80. The vitamin A analogues: 13‐cis retinoic acid, 9‐cis retinoic acid, and Ro 13‐6307 inhibit neuroblastoma tumour growth in vivo
  81. Ketobemidone May Alter Busulfan Pharmacokinetics During High-Dose Therapy
  82. Capillary Gas Chromatography of Trichlorophenols Using Ammonia as Carrier Gas
  83. Capillary Gas Chromatography of Trichlorophenols Using Ammonia as Carrier Gas
  84. Biodistribution of liposomal 131I-VIP in rat using gamma camera
  85. The Somatostatin Analogue Octreotide Inhibits Neuroblastoma Growth in Vivo
  86. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants
  87. In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7–36) amide in the rat studied by gamma camera
  88. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration
  89. Enantiomer separation of underivatized tocainide and related compounds by CGC using ammonia as carrier gas
  90. Enantiomer separation of underivatized tocainide and related compounds by CGC using ammonia as carrier gas
  91. Aspects Concerning Busulfan Pharmacokinetics and Bioavailability
  92. Effect of ammonia on the response of the electron capture detector (ECD)
  93. One Year on Tacrine (THA): Clinical and Biochemical Effects in Patients With Dementia of the Alzheimer Type
  94. Effect of ammonia carrier gas on the response of the flame ionization detector
  95. In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera
  96. Effect of ammonia on the response of the nitrogen phosphorus detector (NPD)
  97. Mixture of ammonia and helium as a carrier gas for capillary gas chromatography
  98. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics
  99. In vivo distribution of [11C]-busulfan incynomolgus monkey and in the brain of a human patient
  100. Capillary gas chromatography of chlorophenols with ammonia as carrier gas
  101. 11C-labeling of busulphan
  102. Capillary gas chromatography of amines with ammonia as carrier gas
  103. Synthesis of [11C]sodium thiocyanate for in vivo studies of anion kinetics using positron emission tomography (PET)
  104. Determination of busulfan in human plasma by gas chromatography with electron-capture detection
  105. Metabolism of14C-busulfan in isolated perfused rat liver
  106. Degradation of busulfan in aqueous solution
  107. Binding of busulfan to plasma proteins and blood cells
  108. Determination of Busulfan in Plasma by GC-MS with Selected-Ion Monitoring
  109. Busulfan kinetics
  110. Gas chromatographic determination of busulfan in plasma with electron-capture detection